Efforts to develop a dengue vaccine aimed at alleviating the fears of those suffering from the disease in Bihar and across India are advancing rapidly. The third phase of clinical trials for the dengue vaccine has commenced in Patna, with six individuals already vaccinated. The trial aims to include approximately 500 participants from Bihar.
Health of vaccine recipients to be monitored over a two-year period
The scientific team will closely monitor the health of vaccine recipients over a two-year period. The Rajendra Memorial Medical Science Research Institute of the Indian Council of Medical Research (ICMR) in Patna is overseeing these clinical trials. According to an official from RMRIMS, the third phase began on September 26, with the initial doses administered to six participants. ICMR will continue to track the health outcomes of these individuals for the duration of the study.
Wider Vaccination Efforts
In collaboration with Panacea Biotech Limited, ICMR plans to vaccinate a total of 10,000 individuals across 19 centers nationwide, including RMRIMS in Patna, where around 500 participants are expected to receive the trial vaccine.
12 deaths due to dengue in Bihar
The dengue situation in Bihar has become concerning, with 123 new cases reported in just 24 hours. This year, there have been 4,416 hospitalizations and 12 deaths attributed to the disease, with 2,184 cases identified in Patna alone. The trial has experienced some delays due to the late arrival of the vaccine, which was expected in July but only arrived in September.
This delay has hindered the opportunity to evaluate the vaccine's efficacy during the active dengue season, as the disease has proliferated in many areas of Patna, creating hotspots of infection.
No comments:
Post a Comment